AACR 2023 | Future prospects of tissue-agnostic treatments

Mohamed Gouda, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the potential future of tissue-agnostic therapies. There are currently five approved targets by the FDA, and by approving more targets, patients will have increased options in terms of treatment. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.